Journal: BMC Nephrology

Article Title: The effect of SGLT2 inhibitor and HIF-PHI on the podocyte-specific molecules and cytoskeleton of diabetic podocytes

doi: 10.1186/s12882-025-04677-0

Figure Lengend Snippet: Effects of high glucose condition, Dapagliflozin, Roxadustat, and combined therapy on the distribution pattern of podocyte-specific molecules in cultured human podocytes. Representative images for nephrin, podocin, podocalyxin, and synaptopodin. Original magnification, ×630. Scale bar: 20 μm. NG, normal glucose (5 mM), HG, high glucose (25 mM), DAPA, Dapagliflozin (11 nM), ROXA, Roxadustat (30 µM)

Article Snippet: To establish podocyte injury in vitro, the differentiated podocytes were starved in medium containing 1% FBS for 12 h first and then subjected to different stimuli for 48 h: (1) normal glucose (NG, 5 mM); (2) high glucose (HG, 25 mM); (3) Dapagliflozin (1.1 nM or 11 nM, MedChemExpress); (4) Roxadustat (3 μM or 30 μM, MedChemExpress).

Techniques: Cell Culture

Journal: BMC Nephrology

Article Title: The effect of SGLT2 inhibitor and HIF-PHI on the podocyte-specific molecules and cytoskeleton of diabetic podocytes

doi: 10.1186/s12882-025-04677-0

Figure Lengend Snippet: Intracellular protein levels of podocyte-specific molecules in cultured human podocytes as determined by indirect immunofluorescence staining: ( A ) nephrin; ( B ) podocin; ( C ) podocalyxin; and ( D ) synaptopodin. Quantification of glomerular nephrin, podocin, podocalyxin, and synaptopodin level by semiquantitative computerized image analysis. Error bars denote standard error of mean (SEM); data were compared by one way analysis of variance (ANOVA) (overall p < 0.01); post hoc comparison between groups was performed by unpaired Student’s t test with adjustment for multiple comparison by the Benjamini-Hochberg procedure. NG, normal glucose (5 mM), HG, high glucose (25 mM), DAPA, Dapagliflozin (11 nM), ROXA, Roxadustat (30 µM)

Article Snippet: To establish podocyte injury in vitro, the differentiated podocytes were starved in medium containing 1% FBS for 12 h first and then subjected to different stimuli for 48 h: (1) normal glucose (NG, 5 mM); (2) high glucose (HG, 25 mM); (3) Dapagliflozin (1.1 nM or 11 nM, MedChemExpress); (4) Roxadustat (3 μM or 30 μM, MedChemExpress).

Techniques: Cell Culture, Immunofluorescence, Staining, Comparison

Journal: BMC Nephrology

Article Title: The effect of SGLT2 inhibitor and HIF-PHI on the podocyte-specific molecules and cytoskeleton of diabetic podocytes

doi: 10.1186/s12882-025-04677-0

Figure Lengend Snippet: Effect of high glucose condition, Dapagliflozin, Roxadustat, and combined therapy on the distribution of F-actin and α-actinin-4 in cultured human podocytes: ( A ) representative images for nephrin (green) and F-actin (red); yellow arrow: podocytes with F-actin relocation; white arrow: co-localization of nephrin and F-actin; ( B ) representative images for nephrin (green) and α-actinin-4 (red); arrows: podocytes with α-actinin-4 relocation. Nuclei were counterstained with DAPI (blue). Original magnification, ×630. Scale bar: 20 μm. The immunofluorescence staining intensities and quantification of glomerular ( C ) F-actin and ( D ) α-actinin-4 levels were measured by semiquantitative computerized image analysis. The intensities of all other treatments are normalized to NG levels. Error bars denote standard error of mean (SEM); data were compared by one way analysis of variance (ANOVA) (overall p < 0.01); post hoc comparison between groups was performed by unpaired Student’s t test with adjustment for multiple comparison by the Benjamini-Hochberg procedure. NG, normal glucose (5 mM), HG, high glucose (25 mM), DAPA, Dapagliflozin (11 nM), ROXA, Roxadustat (30 µM)

Article Snippet: To establish podocyte injury in vitro, the differentiated podocytes were starved in medium containing 1% FBS for 12 h first and then subjected to different stimuli for 48 h: (1) normal glucose (NG, 5 mM); (2) high glucose (HG, 25 mM); (3) Dapagliflozin (1.1 nM or 11 nM, MedChemExpress); (4) Roxadustat (3 μM or 30 μM, MedChemExpress).

Techniques: Cell Culture, Immunofluorescence, Staining, Comparison

Journal: World Journal of Clinical Cases

Article Title: Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report

doi: 10.12998/wjcc.v10.i19.6587

Figure Lengend Snippet: Dynamic changes of hemoglobin and serum ferritin. The patient was admitted to our hospital on July 24, 2020. He was treated with 1.5 units of red blood cell transfusion on that day. After discharge, he began to take 20 mg oral roxadustat three times a week on August 1, 2020. Then he began to take 50 mg oral roxadustat three times a week on December 8, 2020. Hb: Hemoglobin; SF: Serum ferritin.

Article Snippet: Roxadustat (FG-4592, FibroGen, Astellas, AstraZeneca) is one of HIF-PHI and has been listed in China and Japan.

Techniques:

Journal: World Journal of Clinical Cases

Article Title: Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report

doi: 10.12998/wjcc.v10.i19.6587

Figure Lengend Snippet: Changes of serum ferritin and transferrin saturation. The patient’s serum ferritin was as high as 1252.2 mg/L on the second day after blood transfusion on July 25, 2020. His iron index was further improved after taking roxadustat orally in the following months. SF: Serum ferritin; TAST: Transferrin saturation.

Article Snippet: Roxadustat (FG-4592, FibroGen, Astellas, AstraZeneca) is one of HIF-PHI and has been listed in China and Japan.

Techniques: